YD Bio Limited (NasdaqGM: YDES)
Health Care · Biotechnology · TW
$4.34
+45.64% today · -74.5% 1Y
YD Bio Limited (NasdaqGM: YDES) operates in the Biotechnology industry within the Health Care sector. The company is valued at $209.55M and employs 15 people.
Over the last twelve months the share price has lost 74.5%, trading between 1.70 and 25.00.
Tweenvest scores YD Bio Limited across four factors: quality 58/100, value 44/100. Its strongest factor is quality.
YDES price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $209.55M
- Revenue (TTM)
- $510.36K
- P/E
- —
- EPS
- -1.29
- Dividend yield
- —
- Beta (5Y)
- -0.13
- 52-week high
- $25.00
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 70.32M
- Employees
- 15
- Next earnings
- —
About YD Bio Limited
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
- ISIN
- KYG983011076
- Listed since
- Aug 29, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.95 | -1.81% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.